LP
RLMD icon

LMR Partners’s Relmada Therapeutics RLMD Stock Holding History

LMR Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$443K Buy
63,584
+7,984
+14% +$37.8K ﹤0.01% 1099
2025
Q4 		$269K Hold
55,600
– – ﹤0.01% 1231
2025
Q3 		$112K Buy
55,600
+496
+0.9% +$476 ﹤0.01% 1274
2025
Q2 		$33.1K Buy
+55,104
New +$28.3K ﹤0.01% 1237

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

LMR Partners's RLMD Position: Q1 2026 in Review

LMR Partners increased its Relmada Therapeutics (RLMD) stake by 14% in Q1 2026, buying an estimated $37.8K and bringing the position to 63,584 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

LMR Partners first reported a position in RLMD in Q2 2025 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • LMR Partners held 63,584 shares of Relmada Therapeutics worth $443K as of Q1 2026.
  • LMR Partners bought 7,984 Relmada Therapeutics shares in Q1 2026, an estimated $37.8K.
  • Relmada Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1099 holding.
  • LMR Partners first reported a position in Relmada Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.